Ram Waisbourd, VP R&D Strategic Initiatives and
Chief of the R&D Office, Teva Pharmaceutical Industries Ltd Israel
Improving the world
Taking academic discoveries and turning them into innovative drugs for patients
HQ: Petah Tikva, Israel
$20 billion in sales, including $10 billion of innovative branded drugs.
Ram Waisbourd is Chief of the R&D Office and a member of the R&D Leadership Team at Teva. Directly reporting to Teva's President of Global R&D, Ram is responsible for key strategic and operational aspects of Teva's R&D Group.
Ram joined Teva in 2009 and has held various portfolio, integration, and business development positions. Prior to joining Teva, Ram was Vice President of Business Development of XTL Biopharmaceuticals, Vice President of the venture capital fund Biomedical Investments, and a team leader at the strategy consulting firm Shaldor. Ram has a B.Sc. degree from the Wharton Business School and an MBA from Tel-Aviv University.
Teva develops, produces, and markets affordable generic drugs, innovative and specialty pharmaceuticals, and active pharmaceutical ingredients. The company’s line of generic and specialty treatments is backed by global development and manufacturing capabilities, ensuring high quality and accessibility to medicines while reducing costs.
Established in Jerusalem in 1901, the company known today as Teva started out as a small wholesale drug business that distributed imported medications. The business was named S.L.E after its founders Chaim Salomon, Moshe Levin, and Yitschak Elstein. Together, Salomon, Levin, and Elstein opened a small pharmaceutical plant called Assia ("Doctor" in Aramaic) in Petah Tikva. Other plants founded at this time include Zori ("Health" in Hebrew) in Tel Aviv and Teva ("Nature" in Hebrew) in Jerusalem.
With the founding of the State of Israel, the local drug market expanded rapidly. While most pharmaceutical manufacturing companies were privately owned, Teva began trading on the Tel Aviv Stock Exchange in 1951. In 1964, Assia and Zori merged and acquired a controlling interest in Teva. A period of consolidation in the Israeli pharmaceutical industry beginning in the 1960s culminated with the 1976 union of Teva, Assia, and Zori to create Israel’s largest drugmaker, Teva Pharmaceutical Industries Ltd.
In 1984 the U.S. passed the Hatch-Waxman Act, enabling Teva’s entry into generic medicines in America. Through a 50-50 joint venture with W.R. Grace, Teva formed TAG Pharmaceuticals in 1985. The joint company acquired Lemmon in Sellersville, Pennsylvania, facilitating Teva’s entry into the U.S. market. In 1987, Teva began trading on the NASDAQ. The company became full owner of TAG Pharmaceuticals in 1992. Together with Lemmon, this consolidation created Teva Pharmaceutical USA Inc. By the year 2000, through a series of acquisitions, Teva became the largest generic pharmaceutical company in North America. Teva began trading on the NYSE in 2012.
Today Teva has a portfolio of more than 1,000 molecules, producing approximately 64 billion tablets and capsules a year at 66 manufacturing facilities. The company ranks among the 10 top pharmaceutical companies internationally and is active in 60 countries. Approximately 45,000 employees around the world are dedicated to Teva's mission of increasing access to high-quality healthcare for people everywhere at every stage of life.
Company website: www.tevapharm.com